CHF Solutions Expands Commercial Presence in the Middle East with Distribution Arrangement for United Arab Emirates
May 28 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS) today announced the signing of a
distribution agreement with Transimed Medical Equipment Co. LLC
covering the United Arab Emirates, the first distribution
partnership in the Middle East region. The company now has
distribution agreements covering 14 countries outside the U.S.
“This partnership demonstrates our continued commitment to make
ultrafiltration therapy available for patients throughout the
world, as we expand into this new region,” said John Erb, chairman
and CEO of CHF Solutions. “Subject to regulatory approval, we look
forward to working with Transimed to make the simple, flexible and
smart Aquadex SmartFlow™ system available to patients in the U.A.E
suffering from fluid overload due to heart failure, cardiovascular
surgery and other critical care conditions.”
“We are very excited to work with CHF Solutions to introduce
their state-of-the-art technology to the U.A.E. market,” said
Mohammed Zein, CEO of Transimed. “We believe the Aquadex therapy
will make a difference in the quality of lives of heart failure
patients in the UAE. We look forward to a successful partnership
that aims to improve patients’ lives.”
In the United Arab Emirates, over 90,000 patients are treated
annually for heart failure at an overall cost of approximately $500
million.1
About CHF Solutions
CHF Solutions, Inc. (CHFS) is a medical device company dedicated
to changing the lives of patients suffering from fluid overload
through science, collaboration, and innovation. The company is
focused on developing, manufacturing and commercializing the
Aquadex SmartFlow™ system for ultrafiltration therapy. CHF
Solutions is headquartered in Minneapolis, Minn., with wholly-owned
subsidiaries in Australia and Ireland. The company has been listed
on the Nasdaq Capital Market since February 2012.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy
using a simple, flexible and smart method of removing excess fluid
from patients suffering from hypervolemia (fluid overload). The
Aquadex SmartFlow system is indicated for temporary (up to 8 hours)
or extended (longer than 8 hours in patients who require
hospitalization) use in adult and pediatric patients weighing 20 kg
or more whose fluid overload is unresponsive to medical management,
including diuretics. All treatments must be administered by a
health care provider, within an outpatient or inpatient clinical
setting, under physician prescription, both having received
training in extracorporeal therapies.
About Transimed
Transimed Medical Equipment Co. LLC is a medical device
distributor company that covers the United Arab Emirates region.
The company was founded by a team of energetic medical supply
professionals with a deep knowledge of the medical supplies market
in the Middle East and North Africa (MENA) region. Its
representative office in the region is located in Dubai. Transimed
brings state of the art medical solutions to healthcare
professionals. Transimed values its partnership with medical
institutions, partners and takes pride in delivering health
solutions that benefit patients. Transimed is a for profit
organization that does not compromise on the quality of the
products for patient safety and well being.
Forward-Looking Statements
Certain statements in this release may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements about the growth and potential success of
distribution partnerships outside of the U.S., including U.A.E.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our expectations regarding the potential impacts of the COVID-19
pandemic on our business operations, our ability to execute on our
commercial strategy, the possibility that we may be unable to raise
sufficient funds necessary for our anticipated operations, our
post-market clinical data collection activities, benefits of our
products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
our ability to integrate acquired businesses, our expectations
regarding anticipated synergies with and benefits from acquired
businesses, and other risks and uncertainties described in our
filings with the SEC. Forward-looking statements speak only as of
the date when made. CHF Solutions does not assume any obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
1.
https://www.valueinhealthjournal.com/article/S1098-3015(18)31140-9/fulltext
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024